Eli Lilly Stock Pulls Back After Hitting Record Highs Last Week
Eli Lilly and Co. shares are trading lower Wednesday, pulling back from last week's record high despite positive real-world data on Zepbound.
Read original at benzingaStocks · News reference
Obesity Drug Alert: Eli Lilly Study Shows Sustained Zepbound Treatment Reduces Hospital Visits, Medical Costs
New Eli Lilly study reveals that Zepbound significantly lowers monthly healthcare costs for older adults with overweight or obesity.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 26, 2026, 7:30 PM
- Checked
- Aug 26, 2026, 7:30 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Eli Lilly shares are trading lower. The company reported a real‑world study showing Zepbound cut healthcare costs in adults over 55 with obesity, driven by fewer hospitalizations and ER visits.
Read original at benzingaNasdaq 100 Falls as Hot PCE Inflation Stirs Rate-Hike Bets: Stock Market Today
Nasdaq 100 falls 0.6% as traders wait on Nvidia and hot July PCE revives September rate-hike bets. Energy leads, gold sinks 1.3% to $4,599.
Read original at benzinga